BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 38380328)

  • 21. Janus Kinase Inhibitors and Cell Therapy.
    Assal A; Mapara MY
    Front Immunol; 2021; 12():740847. PubMed ID: 34531878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease.
    Tijaro-Ovalle NM; Karantanos T; Wang HT; Boussiotis VA
    Front Immunol; 2019; 10():295. PubMed ID: 30891031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of acute graft versus host disease (GvHD).
    Bacigalupo A; Palandri F
    Hematol J; 2004; 5(3):189-96. PubMed ID: 15167903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.
    Bleakley M; Heimfeld S; Loeb KR; Jones LA; Chaney C; Seropian S; Gooley TA; Sommermeyer F; Riddell SR; Shlomchik WD
    J Clin Invest; 2015 Jul; 125(7):2677-89. PubMed ID: 26053664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
    Chang YJ; Zhao XY; Huang XJ
    Front Immunol; 2018; 9():3041. PubMed ID: 30619371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Corticosteroids for preventing graft-versus-host disease after allogeneic myeloablative stem cell transplantation.
    Quellmann S; Schwarzer G; Hübel K; Greb A; Engert A; Bohlius J
    Cochrane Database Syst Rev; 2008 Jul; (3):CD004885. PubMed ID: 18646116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
    Li JM; Giver CR; Lu Y; Hossain MS; Akhtari M; Waller EK
    Immunotherapy; 2009 Jul; 1(4):599-621. PubMed ID: 20191089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease.
    Abedin SM; Hamadani M
    Expert Opin Investig Drugs; 2020 May; 29(5):423-427. PubMed ID: 32293938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Corticosteroids as graft-versus-host disease prophylaxis for allogeneic hematopoietic cell transplant recipients with calcineurin inhibitor intolerance.
    Puckrin R; Kwan ACF; Blosser N; Leyshon C; Duggan P; Daly A; Zepeda V; Stewart D; Chaudhry A; Storek J; Jamani K
    Cytotherapy; 2023 Oct; 25(10):1101-1106. PubMed ID: 37306643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies.
    Zhang MY; Zhao P; Zhang Y; Wang JS
    PLoS One; 2022; 17(7):e0271979. PubMed ID: 35905125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Case of Multiple Sclerosis-Like Relapsing Remitting Encephalomyelitis Following Allogeneic Hematopoietic Stem Cell Transplantation and a Review of the Published Literature.
    Das J; Gill A; Lo C; Chan-Lam N; Price S; Wharton SB; Jessop H; Sharrack B; Snowden JA
    Front Immunol; 2020; 11():668. PubMed ID: 32431694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.
    Penack O; Marchetti M; Aljurf M; Arat M; Bonifazi F; Duarte RF; Giebel S; Greinix H; Hazenberg MD; Kröger N; Mielke S; Mohty M; Nagler A; Passweg J; Patriarca F; Ruutu T; Schoemans H; Solano C; Vrhovac R; Wolff D; Zeiser R; Sureda A; Peric Z
    Lancet Haematol; 2024 Feb; 11(2):e147-e159. PubMed ID: 38184001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease.
    Mohamed FA; Thangavelu G; Rhee SY; Sage PT; O'Connor RS; Rathmell JC; Blazar BR
    Front Immunol; 2021; 12():757836. PubMed ID: 34712243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
    von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
    BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC.
    Laisne L; Neven B; Dalle JH; Galambrun C; Esvan M; Renard C; Rialland F; Sirvent A; Gandemer V;
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28233. PubMed ID: 32614145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging drugs for graft-versus-host disease.
    Kekre N; Antin JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):209-18. PubMed ID: 27007595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease.
    Choi J; Cooper ML; Staser K; Ashami K; Vij KR; Wang B; Marsala L; Niswonger J; Ritchey J; Alahmari B; Achilefu S; Tsunoda I; Schroeder MA; DiPersio JF
    Leukemia; 2018 Nov; 32(11):2483-2494. PubMed ID: 29691471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-Apoptotic Molecule BCL2 Is a Therapeutic Target in Steroid-Refractory Graft-Versus-Host Disease.
    Strobl J; Pandey RV; Krausgruber T; Kleissl L; Reininger B; Herac M; Bayer N; Krall C; Wohlfarth P; Mitterbauer M; Kalhs P; Rabitsch W; Bock C; Hopfinger G; Stary G
    J Invest Dermatol; 2020 Nov; 140(11):2188-2198. PubMed ID: 32247860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment.
    Holler E
    Best Pract Res Clin Haematol; 2007 Jun; 20(2):281-94. PubMed ID: 17448962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.